Good afternoon, ladies and gentlemen, and welcome to the Cytosorbents' First Quarter 2026 Earnings Conference Call. Operator provided instructions. As a reminder, this call is being recorded. And now I would like to turn the conference over to Pete Mariani, Chief Financial Officer. Please go ahead.

Thank you, Kathleen, and good afternoon, everyone. Welcome to Cytosorbents' First Quarter 2026 Conference Call. Joining me today is Dr. Phil Chan, our Chief Executive Officer; and Dr. Makis Deliargyris, our Chief Medical Officer. Before I turn the call over to Phil, I'd like to remind listeners that during the call, management's prepared remarks may contain forward-looking statements, which are subject to risks and uncertainties. Management may make additional forward-looking statements in response to your questions. Therefore, the company claims protection under the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual results may differ from results discussed today. The forward-looking statements may reflect our views and estimates as of today, May 13, 2026, and we assume no obligation to update these projections in the future as market conditions change. We encourage investors to review the risks discussed in our annual report on Form 10-K filed with the SEC on March 30, 2026, and as updated by the risks reported in our quarterly reports on Form 10-Q and in press releases and other communications to shareholders issued from time to time. During today's call, we will have an overview presentation covering the operating and financial results for the first quarter of 2026 and provide a regulatory update on our process to obtain U.S. marketing approval for DrugSorb-ATR. Following the presentation, we will open the lines to analysts for questions. And now I'll turn the call over to Phil. Phil?

Thank you very much, Pete, and good afternoon, everyone. Before I start, I'd like to remind everyone of the current regulatory status of our products. CytoSorb is commercially approved in the European Union and many international markets for multiple indications including cytokine removal, bilirubin and myoglobin removal and removal of certain antithrombotic agents during cardiothoracic surgery. However, CytoSorb is not currently approved or cleared in the United States or Canada outside of its prior emergency use authorization during COVID-19. Similarly, DrugSorb-ATR remains an investigational device and is not commercially approved in any geography at this time. I'll begin with an operational overview of the quarter and our continued efforts to strengthen and streamline the business, while positioning the company for future growth. Cytosorbents today is built around a differentiated blood purification platform technology designed to remove harmful substances directly from the bloodstream in critically ill and cardiac surgery patients. What continues to make this business attractive is the combination of a high-value therapy with a highly scalable razor blade type recurring revenue model that integrates into the existing blood pump infrastructure in hospitals. Our core CytoSorb business continues to expand internationally, generating core product sales of more than $37 million in 2025 with over 300,000 devices used cumulatively in more than 70 countries around the world. At the same time, DrugSorb-ATR represents a potentially transformational opportunity in cardiac surgery and blood thinner removal. We continue to believe the unmet need here is substantial. And importantly, we now have clear direction from FDA regarding the path forward. We will also discuss a potential parallel path to U.S. regulatory approval as well. Turning to our first quarter performance. Revenue grew 2% year-over-year to $8.9 million, despite several temporary external headwinds. One of the most encouraging developments was the continued deceleration in our Direct International business outside Germany, which grew 13% year-over-year. We believe this reflects improving physician awareness, stronger execution and increased adoption in key accounts, particularly driven by an outstanding team. In Germany, sales declined mostly year-over-year. But operationally, we are actually very encouraged by the progress we're seeing. Our smaller and more focused commercial organization is executing better, productivity has improved and customer engagement has strengthened under new leadership. As we stabilize the market, we plan to selectively rebuild portions of the sales force to expand coverage and reaccelerate growth. Distributor sales were flat overall, but were negatively impacted by geopolitical disruption in the Middle East, particularly surrounding the U.S. Iran war, which delayed approximately $0.5 million in expected orders, primarily affecting our Dubai subsidiary and portions of the broader EMEA region. From a margin perspective, gross margins remained strong at 69%. The modest decline versus last year was intentional as we strategically slowed production levels to reduce inventory and improve working capital efficiency. Importantly, we continue to make operational improvements within manufacturing that we believe will support future profitability. One of the most important areas of progress for CytoSorb globally has been the continued refinement of how physicians use the therapy in clinical practice. Increasingly, we believe successful outcomes depend on identifying the right patient, initiating therapy at the right time and applying the appropriate treatment intensity or in other words, a dosing strategy. This evolving treatment paradigm is helping physicians optimize the use of CytoSorb across a wide variety of highly acute and often life-threatening conditions. Today, CytoSorb is being used in many conditions, including septic shock, trauma, rhabdomyolysis, liver failure, acute respiratory distress syndrome, cytokine storm, many different types of infectious diseases, post-surgical complications, transplant medicine, pancreatitis and increasingly blood thinner removal during cardiac surgery, just to name a few. We are working to define what the right patient looks like in each of these situations. Meanwhile, we continue to teach centers that early intervention is critical to the success of our therapy. This right timing is being enabled by our stand-alone PuriFi pump that enables easy treatment without a patient needing to be in renal failure on dialysis. We have placed more than 100 of these pumps internationally and believe it's an important part of our enablement strategy. Furthermore, just like antibiotics, to have the best outcome and to fully control the out-of-control inflammatory response users need to treat for the right duration and intensity. This right dosing is being facilitated by our recent launch of the HotSwap device, which enables the rapid exchange of CytoSorb devices. It continues to generate excellent reviews. As physicians gain more experience with the technology and treatment protocols continue to evolve, we believe this growing body of real-world experience strengthens both the clinical value proposition, the clinical conviction and the commercial opportunity for the platform. In addition to the clinical performance, we continue to see growing evidence supporting the economic value proposition of our CytoSorb therapy. This study from a Swiss high-volume center evaluated 246 septic shock patients and demonstrated important differences in outcomes between standard of care alone and standard of care plus CytoSorb therapy. Despite treating sicker patients at baseline, the CytoSorb group demonstrated significantly shorter ICU stays, shorter overall hospital stays and reduced ventilation times for survivors that averaged approximately six to seven days. Also, CytoSorb significantly lowered nursing workload intensity. Importantly, these operational improvements translated into meaningful improved financial outcomes for the hospital system itself with significantly higher net earnings per patient case. We believe this type of data is increasingly important in today's health care environment where hospitals are under growing pressure to improve efficiency, optimize ICU resource utilization, reduce length of stay and manage staffing burdens. The ability to potentially improve both clinical and economic outcomes simultaneously remains an important differentiator for our technology. At this point, I'll turn the call over to Dr. Makis Deliargyris, our Chief Medical Officer, to discuss our clinical and regulatory progress. Makis?

Thank you, Phil, and good afternoon to everyone joining our call. Before we move on to the regulatory updates, it's important to review, once again, the problem that we're trying to solve with DrugSorb-ATR. And that problem is blood thinners and cardiac surgery. As of today, tens of millions of patients worldwide are on direct oral anticoagulants like Eliquis or Xarelto or antiplatelet agents like Brilinta that they take either acutely to reduce risks of heart attacks or chronically to reduce their risk of stroke, new heart attacks or serious thrombotic complications. These patients, on average, need surgery about 1% to 2% of them every year, frequently emergent surgery, which usually is cardiac surgery since they suffer from cardiovascular disease. Specifically, among all emergency cardiac procedures, about 5% to 10% of patients are on chronic drug therapy at the time of surgery. Similarly, among heart attack patients who are treated with antiplatelet drugs like Brilinta, about 5% to 10% of them are not eligible for a stent and do require urgent CABG surgery. The problem arises because blood thinners when present during surgery significantly and substantially increase the risk for severe, frequently life-threatening bleeding. Currently, the only option for these patients is to delay surgery for multiple days and to allow for drug clearance out of the body. However, this is far from a perfect solution. First of all, many patients simply cannot wait. The situation is too acute, too critical, and they cannot afford multiple day delays and need to proceed for emergency surgery. Second, even among those who can wait, they are exposed to potentially additional complications during this waiting period, severe complications, including death, and at the same time, they're consuming valuable hospital resources like intensive care beds simply waiting for a drug to wash out. And this is where DrugSorb-ATR, a twice-designated FDA Breakthrough Device, has the potential to address this pervasive and serious unmet medical need. Next slide, please. In terms of our FDA regulatory update for DrugSorb-ATR and Brilinta, it is important to remind our audience that in August of 2025, we received the FDA decision on the original de novo submission. FDA upheld the prior denial decision and required additional information, primarily related to real-world evidence on clinical outcomes to support the company's desired label claim that would have to be included in a new de novo submission. However, there were two very important and very positive outcomes of the appeal process and outlined in the appeal decisions. First of all, FDA did not identify any issues with device safety, which is key to the benefit-risk ratio that FDA uses to judge de novo approval. Second, it's our understanding that FDA agreed that the upcoming submission would be focused only on the remaining open items, potentially giving the opportunity for a focused and expedited review. In January 2026, we held a formal pre-submission meeting with FDA and have since continued to have interactive discussions with FDA to confirm the requirements for the new de novo submission, including whether all the requested information would be needed in the submission itself or whether it could be a post-marketing requirement. During these discussions, FDA has requested that additional mechanistic data be included together with the real-world evidence within the new de novo submission. Accordingly, we are evaluating the options to generate the additional mechanistic data which we plan to discuss with FDA and incorporate their feedback before completing the required work. This will likely delay the new de novo application submission to late 2026 or early 2027. However, we now have a clear direction from FDA, and we plan to file as soon as possible. Following submission, a regulatory decision is typically expected within a 150-day review period, although timelines may be accelerated or extended based on the nature and scope of FDA interactions during the review process. Next slide. Meanwhile, the main results of the STAR-T randomized clinical trial are now published and available online. In the paper that you see on the slide, the principal investigators of the study, together with the executive committee and the top enrollers, summarize the main observations from the STAR-T trial. The paper is available online, open access, which means you can feel free to download it for free, and we urge you to do so and read it in great detail. However, we'd like to highlight the central message as the authors and the editors of the journal selected. By the way, it's important to note that the journal that published the paper is the most read journal by American cardiac surgeons, The Journal of Thoracic and Cardiovascular Surgery. In the central message, the authors concluded that DrugSorb-ATR used for ticagrelor removal is safe and can reduce the severity of bleeding after isolated CABG in patients operated within two days of drug discontinuation. And what you see on the graph is a more than 50% reduction in the composite of severe bleeding events either defined by a standardized bleeding definition or via the volume of blood loss after surgery, with the use of the device. Next slide. Today, we would also like to share an additional regulatory update and a potential parallel regulatory pathway goal, specifically relating to the removal of DOAC. We have previously discussed our intention to pursue an expanded label for DrugSorb-ATR to include the removal of direct oral anticoagulants following initial marketing approval for ticagrelor removal. However, meanwhile, real-world evidence and publications continue to grow for the DOAC removal indications. As such, within the next 30 days, we plan to submit a separate pre-submission request to FDA to review the data that is currently available for the DOAC indication and determine what, if any, additional information may be required to support a parallel de novo submission for DOAC removal. This strategy is consistent with the already received second FDA Breakthrough Device designation for DrugSorb-ATR to remove drugs during cardiac surgery. As we previously stated, tens of millions of these patients are on chronic or lifelong DOAC for diseases such as atrial fibrillation, deep venous thrombosis or pulmonary embolism. In fact, Eliquis is the number seven pharmaceutical in the world with $14.4 billion in global sales in 2025, whereas Xarelto is also a blockbuster with $5.1 billion in sales in 2025, and they are the market leaders of the category. Therefore, potential FDA marketing approval for both Brilinta and DOAC removal in cardiac surgery could expand the total addressable market for DrugSorb-ATR to $500 million up to $1 billion in the U.S. alone. Next slide, please. Finally, I'd like to share some exciting news about some upcoming presentations in two very important cardiovascular conferences. The evidence base for antithrombotic removal in cardiac surgery continues to grow. And as such, we have been submitting original analyses to some of the most attended conferences worldwide. Specifically at the EuroPCR meeting that is taking place next week in Paris, which happens to be the world's leading course in interventional cardiology, we have two key presentations that will be made on antithrombotic removal. The first one titled 'Urgent CABG in ACS, impact of P2Y12 inhibitor choice and intraoperative hemoadsorption on perioperative bleeding, a propensity score matched analysis of real-world data.' This is a comparison of strategies employed today in everyday practice. We're comparing outcomes from hospitals that use routinely ticagrelor and our device during urgent surgery versus the outcomes observed among hospitals who opt for a different antiplatelet drug, like clopidogrel or Plavix and do not use the device. Using sophisticated statistical methods to ensure that the populations are comparable, we're able to see the difference the choice of P2Y12 and device use can make when it comes to bleeding. The second presentation, specifically on DOAC removal during CABG, is going to be the first data we present to this audience. These are data that are coming from the STAR registry, again, showing that it's not just Brilinta, but also Eliquis and Xarelto that are frequently on board in patients who require urgent CABG. Later this year, in Munich at ESC 2026, which is taking place at the end of August, which happens to be the world's largest cardiovascular conference, we have two additional analyses being presented on antithrombotic removal during cardiac surgery. Again, we're talking about ticagrelor removal during urgent CABG, but we're comparing to hospitals who also use ticagrelor, but do not use the device. Again, very sophisticated statistical methods are being employed on patient-level data to ensure these populations are appropriate for comparison. And then finally, a very exciting analysis from the collection of German heart centers who have incorporated their device as part of their routine care to treat multiple different types of blood thinners. So this analysis is not specific to any one blood thinner, but simply the strategy of using a device whenever patients on blood thinners require urgent CABG. Now this analysis and the data are embargoed until the date of release at the conference, so we cannot go into more details. But obviously, we're very excited about the release of this new data that we believe highlights the increasing adoption of our technology by leading heart centers in Europe and their enthusiasm around the reductions in bleeding they're experiencing with the use of our device as part of their protocols for patients on blood thinners. It's important to note that it's very difficult to get any analysis accepted, these are very competitive conferences. So I think that also shows the enthusiasm among the broader cardiovascular community, even among those who do not have access to the device, about learning the potential benefit of this novel solution in their everyday practice. So thank you for your attention. And with that, I will turn it over to Pete now.

Thank you, Makis, and good afternoon, everyone. Today, I'll be reviewing the first quarter 2026 financial performance and important updates that continue to strengthen our business. First quarter revenue, as Phil noted, was $8.9 million, an increase of 2% over prior year and down 7% on a constant currency basis. As Phil noted, first quarter revenue includes approximately 13% growth of our International Direct markets, partially offset by lower revenue in our direct German market. Although our direct German sales were down over the prior year, we continue to see signs of improved leadership and sales processes, account targeting and customer engagement with a smaller and more focused team and plan to selectively expand this team to improve account coverage and drive growth across cardiac surgery and critical care. Distributor sales were flat year-over-year as progress across several territories was offset by delayed distributor orders of approximately $500,000 in parts of the Middle East and neighboring regions due to geopolitical and economic instability related to the U.S. Iran war. This unexpected disruption has slowed the anticipated growth of our recently established subsidiary in Dubai, although we expect conditions to improve as the conflict stabilizes. Gross margins for Q1 were 69% compared to 71% in the prior year. The lower gross margin reflects a planned reduction in unit production in the quarter, which allowed us to improve working capital and cash burn by lowering inventory levels to $4.8 million at the end of the quarter compared to $5.3 million at the end of the year. Operating expenses were $9.2 million for the quarter compared to $10.1 million a year ago. The year-over-year decrease reflects lower research and development and clinical project spend and other compensation costs reflecting initial benefits of our strategic headcount and cost reduction program implemented in the fourth quarter of last year. We expect the costs will continue to decrease sequentially as a full benefit of our cost reduction program develops across the next few quarters. Our operating loss improved approximately 22% in Q1 to $3 million compared to $3.9 million in the prior year, reflecting the lower operating expenses. Net loss increased to $5.1 million for the quarter or $0.08 per share compared to a net loss of $1.5 million or $0.02 per share in the prior year and it's primarily due to the noncash impact of changes in foreign currency transactions year-over-year. However, adjusted net loss for the quarter which removes the noncash impact of foreign currency gains and losses and noncash stock compensation improved to $3.4 million or $0.05 per share compared to an adjusted net loss of $3.7 million or $0.06 per share in the prior year. Adjusted EBITDA loss for the quarter, which also removes the noncash impact of foreign currency gains and losses and noncash stock compensation, improved to $2.2 million compared to an adjusted EBITDA loss of $2.7 million in the prior year. Our total cash, cash equivalents and restricted cash was approximately $6.4 million on March 31 compared to $7.8 million at the end of the year. Total cash burn in the quarter improved to $1.1 million, excluding $300,000 of restructuring-related payments in the quarter. The improvement reflects the initial benefit of our cost reduction program and improved working capital dynamics in the quarter. In the fourth quarter of 2025, we implemented the strategic workforce and cost reduction initiative, reducing headcount by approximately 10%, while lowering operating and production expenses. The initial benefits of this program were reflected in lower operating expenses and improved margins in the first quarter, and we have continued to make additional operational improvements and taken further steps to reduce costs in the first quarter and believe these actions will continue to drive improvements in the coming quarters in support of our goal of achieving operating cash flow breakeven in the second half of the year. Now I'll turn the call back over to Phil.

Thanks, Pete. Overall, while the first quarter included both macroeconomic and geopolitical challenges related to the U.S. Iran war, we believe the company continues to make meaningful progress across multiple fronts. Operationally, we are improving efficiency and stabilizing key markets. Clinically, the evidence base supporting both CytoSorb and DrugSorb-ATR continues to strengthen, and strategically, we now have greater clarity regarding the FDA pathway moving forward with a dual pathway potentially possible. Overall, we believe Cytosorbents today represents a compelling combination of an established commercial platform business together with a potentially transformative regulatory growth opportunity. The core CytoSorb business continues generating recurring high-margin revenue globally across critical care and cardiac surgery. Meanwhile, DrugSorb-ATR provides potential long-term upside through two FDA Breakthrough Device designations, targeting large unmet needs in cardiac surgery patients on blood thinners. At the same time, we are remaining disciplined financially and operationally as we work towards achieving operating cash flow breakeven in the second half of this year. We believe the company is becoming leaner, more focused, operationally stronger and better positioned for long-term sustainable growth and shareholder value creation. With that, thank you again for joining us today and for your continued support of Cytosorbents. Operator, we are now ready to begin the question-and-answer session.

Operator provided instructions. Your first question comes from the line of Michael Sarcone of Jefferies.

Yes, Phil, thanks for the update around DrugSorb and the regulatory environment. I was wondering if you could elaborate more. You talked about the FDA is requesting additional mechanistic data being included in your new de novo submission. Can you maybe just talk about what are the various scenarios or forms that that data could take. And what would be the kind of requisite investment required on the part of Cytosorbents?

Yes. Thanks, Mike. Let me actually turn it over to Makis to answer that question, and I can provide some additional color after that. Makis?

Yes. Thanks, Phil. And Michael, thank you for the question. So basically, the term mechanistic data refers to the fact that we're being asked for nonclinical data. These are data to support the mechanism of action of the device. Now these data generally do not require the resourcing of running a clinical trial, and I think that's why we wanted to make that distinction. These are nonclinical studies we're being asked to run; it's more of experimental designs that will provide this additional information. So we are assessing the options that we have right now in exactly what type of experiments can generate the information. We're working together with FDA to finalize those designs. We don't have them finalized yet. And as such, we can't comment with any more detail about what that data would look like. However, I just want to make sure that it's clear that these are nonclinical studies that do not require long duration of clinical follow-up or multiple patients or multiple sites working together, and therefore, they do not require the heavy resources of running a clinical trial. Once we have more clarity and we're able to come to an alignment with FDA, I think at that time, we would potentially disclose more information around the design of these experiments.

Okay. And I mean, for my own understanding, could that include something like real-world evidence or registry data from a single site? Is that something that could address something like this?

Yes. I think it's important to understand that these are nonclinical data we're looking for, right? So this is not necessarily to expand the existing real-world evidence that we have, this is supplementary information around the mechanism of action of the device. So these are not clinical outcome trials or experiments that we're talking about.

And then I guess, my second question, on the potential for expanding the label to DOACs, I guess what is your hope when you submit for a pre-submission meeting with the FDA to review some of the data? In the best case scenario, what do you hope the FDA comes back with in terms of the easiest pathway and the most efficient pathway towards getting this expanded label?

I think that's an excellent question, Michael. But to be able to truly give you an answer that's meaningful, that would have to happen after we meet with the FDA. What we're saying today on the update is that we believe we have enough information to go ahead in front of them and basically leverage some of the real-world experience with the device and some of the accumulating publications and data that are out there and see what they would need in addition to what we already have, which may not even be much. We just don't know how they're going to view the DOAC application in comparison. We do have clarity with ticagrelor and Brilinta, but we want to gain similar clarity with DOAC and we want to have that alignment early on. That's why now that we believe there's a substantial body of evidence already collected, we want to be able to present to them so we can move forward with due diligence in a timely fashion to be able to compile the necessary information and proceed with the parallel de novo submission for DOAC removal.

And your next question comes from the line of Tom Kerr.

A couple of business questions. We don't talk much about the Middle East business. Can you expand on that? Which country? Is it all distributor business? Or is there any direct sales in the Middle Eastern region? Just any more color on that.

Yes. Last year, we established our subsidiary in Dubai, UAE and talked about the exciting opportunities in the Middle East, particularly in large countries like Saudi Arabia, where if you look at the historical publications coming out of the Middle East, Saudi Arabia, for example, has been one of the thought leaders in the use of our therapy in COVID initially, but also in other applications. But the Middle East is a broad territory, and we believe that there's actually a lot of opportunity given the general wealth in the region and the high quality and standards of medical care. Now obviously, the U.S. Iran war was unexpected. And I think, as you've seen, it has many implications across the world economy and in particular the Middle East, where there's been a lot of near-term uncertainty. However, despite some of the back and forth that has gone on in that region, we do feel that this conflict is temporary and that ultimately, a resolution to these issues will be found. We are planning to be ready to respond in that case. And I would also note that a lot of the conflict creates a lot of injury to a lot of people, and that is exactly what our therapy is designed to help with. So we believe that everything that's happening right now just makes it even more compelling what our technology can help do.

Got it. All right. That makes sense. One more finance question. On the gross margins and inventory, sorry if I missed this, but are the inventory levels where you want to be? Or will there be continued sort of drag on gross margin this quarter or next quarter?

Yes, Tom, we're — I think our inventory levels will continue to come down a little bit. So I think that instead of accelerating gross margins, I think they'll be in that high 60s to low 70s range here until we balance this out a bit more. But we have that opportunity to do so before we have to really accelerate revenue or inventory production again. The organization, along with that, has taken out a significant amount of costs and really reorganized the way they are doing ordering and planning, and I think that we have an ability to see efficiencies through this time that may not negatively impact margins going forward.

And your next question comes from the line of Sean Lee.

I just have a couple on the commercial side. With regards to Germany, you mentioned that you're seeing good signs of a turnaround and expect to grow the sales force there again. So I was wondering when do you expect the overall German market to inflect back to growth? And what's the expected cost of the sales expansion that you're looking at?

Yes. I think that what we saw in the first quarter was very encouraging progress across the German organization. And again, we nearly matched sales from a year ago with a smaller, more focused sales force. The way that we have sourced our headcount in Germany and in many other countries is that it is typically a lower fixed salary, coupled with an opportunity to earn quite a lot on the upside with a higher variable component. In fact, most medical device companies do this across the board. But it's a way to be able to control that initial spend as the sales team gets up to speed and becomes productive. So we believe that out of the gate, those sales reps will be able to pay for themselves with just the initial business that they're doing. And as they become much more productive, they'll help to contribute to the overall growth of the organization. Germany is an 87 million population country, it's huge. And it has many hospitals, around 1,900 hospitals within the country, and it's a lot of work for a small sales team to cover. And so I think we truly believe that there's a lot of opportunity as we begin to reshape our commercial organization in Germany to really just get beyond treading water and staying even to actually returning to growth. But I think that's what a lot of this operational efficiency, driving performance by metrics and strong leadership is all about. And that's what we're encouraged by from the recent progress that we've made.

Great. My second question is on the direct sales outside Germany, which seems to grow really well, with 13% this quarter. Could you elaborate a bit on the primary drivers behind this growth? And why it's so different from what we've seen in Germany, at least in the previous quarters?

Well, first of all, I think that they benefit from growing on a smaller base of revenue, but I do believe that it's really based upon the leadership as well as the individual team effort in individual countries that is driving that growth. Historically, it's been Germany, Austria, Switzerland, but it has continued to progress to other countries like Poland and the Netherlands and countries in the U.K., such that we consider all the time about looking to increase the number of direct territories that we're actually selling into. The teams are very scrappy about how they approach market development. They are very hands on, very in touch with their customers, looking to teach all the different strategies and applications that are well known in more developed countries like Germany, Austria and Switzerland. So I think the teams are doing well, and we continue to work to improve operational efficiency even in these teams, and we think that will also pay dividends in the future.

My last question is on the Middle East. You mentioned that there were $0.5 million of delayed distributor orders. Do you feel that that's still recoverable either in Q2 or later this year? And do you expect to see a continued impact in the region as well?

Yes, Sean, I think the answer to that is yes. We had orders that were submitted and needed to be canceled at the last minute and orders under development that did not come in during the month of March. Those are all reflective of the development work our team is doing in the Middle East to get those, in some cases, new distributors and in others existing distributors, up and running and focused on the business. We've seen a lot of increased activity at conferences across the Middle East, a lot of excitement of physicians across the Middle East at these conferences. There's a growing amount of interest in this region, and we are confident that although I don't expect a snap back when things settle down, over the months following stability in the Middle East, those distributors are going to be ready to move and take inventory and start distributing again.

There are no further questions at this time. I will now turn the call back over to Phil Chan for the closing remarks.

Well, again, everyone, we appreciate your support of the company and look forward to updating you on our continued progress throughout the year. We look forward to giving you an update, hopefully, on the regulatory process in the near future. Thank you again. And if you have any questions, please feel free to reach out to [email protected], and we'll try to answer those questions as best we can. Thank you so much. Have a good night.

Ladies and gentlemen, this concludes today's conference call. Thank you all for joining. You may now disconnect.